Galgiani JN - Search Results

1

Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis.

Grizzle AJ, Wilson L, Nix DE, Galgiani JN. Grizzle AJ, et al. Among authors: galgiani jn. Open Forum Infect Dis. 2020 Dec 28;8(2):ofaa623. doi: 10.1093/ofid/ofaa623. eCollection 2021 Feb. Open Forum Infect Dis. 2020. PMID: 33575419 Free PMC article.

2

Coccidioidomycosis as a common cause of community-acquired pneumonia.

Valdivia L, Nix D, Wright M, Lindberg E, Fagan T, Lieberman D, Stoffer T, Ampel NM, Galgiani JN. Valdivia L, et al. Among authors: galgiani jn. Emerg Infect Dis. 2006 Jun;12(6):958-62. doi: 10.3201/eid1206.060028. Emerg Infect Dis. 2006. PMID: 16707052 Free PMC article.

3

Pharmacokinetics of nikkomycin Z after single rising oral doses.

Nix DE, Swezey RR, Hector R, Galgiani JN. Nix DE, et al. Among authors: galgiani jn. Antimicrob Agents Chemother. 2009 Jun;53(6):2517-21. doi: 10.1128/AAC.01609-08. Epub 2009 Apr 6. Antimicrob Agents Chemother. 2009. PMID: 19349517 Free PMC article. Clinical Trial.

4

Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs.

Shubitz LF, Roy ME, Nix DE, Galgiani JN. Shubitz LF, et al. Among authors: galgiani jn. Med Mycol. 2013 Oct;51(7):747-54. doi: 10.3109/13693786.2013.770610. Epub 2013 Mar 14. Med Mycol. 2013. PMID: 23488972

5

Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, Orbach MJ, Galgiani JN. Nguyen C, et al. Among authors: galgiani jn. Clin Microbiol Rev. 2013 Jul;26(3):505-25. doi: 10.1128/CMR.00005-13. Clin Microbiol Rev. 2013. PMID: 23824371 Free PMC article. Review.

6

Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials.

Shubitz LF, Trinh HT, Perrill RH, Thompson CM, Hanan NJ, Galgiani JN, Nix DE. Shubitz LF, et al. Among authors: galgiani jn. J Infect Dis. 2014 Jun 15;209(12):1949-54. doi: 10.1093/infdis/jiu029. Epub 2014 Jan 12. J Infect Dis. 2014. PMID: 24421256 Free PMC article.

7

Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity.

Donovan FM, Ramadan FA, Lim JR, Buchfuhrer JE, Khan RN, DeQuillfeldt NP, Davis NM, Kaveti A, De Shadarevian M, Bedrick EJ, Galgiani JN. Donovan FM, et al. Among authors: galgiani jn. Open Forum Infect Dis. 2022 Jan 27;9(3):ofac032. doi: 10.1093/ofid/ofac032. eCollection 2022 Mar. Open Forum Infect Dis. 2022. PMID: 35169593 Free PMC article.

8

Coccidioidomycosis: clinical update.

Ampel NM, Wieden MA, Galgiani JN. Ampel NM, et al. Among authors: galgiani jn. Rev Infect Dis. 1989 Nov-Dec;11(6):897-911. doi: 10.1093/clinids/11.6.897. Rev Infect Dis. 1989. PMID: 2690287 Review.

9

Vaccines to prevent systemic mycoses: holy grails meet translational realities.

Galgiani JN. Galgiani JN. J Infect Dis. 2008 Apr 1;197(7):938-40. doi: 10.1086/529205. J Infect Dis. 2008. PMID: 18419469 Free PMC article. No abstract available.

10

Coccidioidomycosis among scholarship athletes and other college students, Arizona, USA.

Stern NG, Galgiani JN. Stern NG, et al. Among authors: galgiani jn. Emerg Infect Dis. 2010 Feb;16(2):321-3. doi: 10.3201/eid1602.090918. Emerg Infect Dis. 2010. PMID: 20113571 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235 results

Search Page

Filters